CIR Circadian Technologies Changes Name to Opthea |
11/12/15 | | 46.88KB | Share |
|
CIR Initial Director's Interest Notice - MS |
04/12/15 | | 85.4KB | Share |
|
CIR Initial Director's Interest Notice - GK |
04/12/15 | | 64.47KB | Share |
|
CIR Final Director's Interest Notice - TM |
04/12/15 | | 63.9KB | Share |
|
CIR Final Director's Interest Notice - RH |
04/12/15 | | 63.27KB | Share |
|
CIR Final Director's Interest Notice - DF |
04/12/15 | | 64.68KB | Share |
|
CIR Circadian Receives $3M R&D Tax Incentive |
02/12/15 | PRICE SENSITIVE | 45.4KB | Share |
|
CIR Circadian Board Changes and Renewal |
30/11/15 | PRICE SENSITIVE | 258.54KB | Share |
|
CIR Results of the Annual General Meeting |
30/11/15 | | 54.72KB | Share |
|
CIR CEO Presentation for the Annual General Meeting |
30/11/15 | | 1.89MB | Share |
|
CIR Chairman's address to the Annual General Meeting |
30/11/15 | | 66.46KB | Share |
|
CIR Trading Halt |
30/11/15 | PRICE SENSITIVE | 257.45KB | Share |
|
CIR Circadian/Opthea presentation at OIS 2015 |
13/11/15 | | 1.38MB | Share |
|
CIR Circadian to Present at US Ophthalmology Innovation Summit |
10/11/15 | | 267.11KB | Share |
|
CIR Notice of Annual General Meeting and Proxy Form |
30/10/15 | | 765.9KB | Share |
|
CIR Circadian to regain VEGFR-3 intellectual property license |
23/10/15 | PRICE SENSITIVE | 47.36KB | Share |
|
CIR Appendix 4G |
30/09/15 | | 130.3KB | Share |
|
CIR Annual Report 2015 |
30/09/15 | | 1.06MB | Share |
|
CIR Change in substantial holding |
07/09/15 | | 233.88KB | Share |
|
CIR Appendix 4E and Annual Financial Report 2015 |
19/08/15 | PRICE SENSITIVE | 935.84KB | Share |
|
CIR Circadian Corporate Presentation - July 2015 |
09/07/15 | | 1.89MB | Share |
|
CIR Change of Director's Interest Notice - DF |
02/07/15 | | 76.67KB | Share |
|
CIR Change of Director's Interest Notice - MB |
02/07/15 | | 73.44KB | Share |
|
CIR Appendix 3B |
02/07/15 | | 233.75KB | Share |
|
CIR Circadian Commences Wet AMD OPT-302 Clinical Trial |
01/07/15 | PRICE SENSITIVE | 256.43KB | Share |
|
CIR Change in substantial holding |
25/06/15 | | 141.68KB | Share |
|
CIR Circadian receives IND approval from FDA for Wet AMD Phase 1 |
15/06/15 | PRICE SENSITIVE | 257.43KB | Share |
|
CIR Circadian partner Eli Lilly presents IMC-3C5 Ph1 at ASCO |
02/06/15 | PRICE SENSITIVE | 829.98KB | Share |
|
CIR OPT-302 Data Presented at Major Ophthalmology Conferences |
07/05/15 | | 167.63KB | Share |
|
CIR Circadian Shareholder Newsletter April 2015 |
16/04/15 | | 850.85KB | Share |
|
CIR Half Year Report and Accounts |
26/02/15 | PRICE SENSITIVE | 571.22KB | Share |
|
CIR US Patent Granted for Soluble VEGFR-3 Traps |
28/01/15 | PRICE SENSITIVE | 179.31KB | Share |
|
CIR Circadian Receives $2.2M R&D Tax Incentive |
23/01/15 | PRICE SENSITIVE | 38.07KB | Share |
|
CIR Appendix 3B |
15/01/15 | | 151.76KB | Share |
|
CIR Change of Director's Interest Notice - DF |
23/12/14 | | 76.68KB | Share |
|
CIR Change of Director's Interest Notice - MB |
23/12/14 | | 74.31KB | Share |
|
CIR Appendix 3B |
23/12/14 | | 157.61KB | Share |
|
CIR Circadian Announces Formation of Clinical Advisory Board |
03/12/14 | | 251.52KB | Share |
|
CIR Ceasing to be a substantial holder |
27/11/14 | | 110.09KB | Share |
|
CIR Placement Cleansing Notice |
27/11/14 | | 53.31KB | Share |
|
CIR Becoming a substantial holder |
26/11/14 | | 608.53KB | Share |
|
CIR Completion of Placement and Appendix 3B |
25/11/14 | | 199.36KB | Share |
|
CIR Change in substantial holding |
25/11/14 | | 135.33KB | Share |
|
CIR Becoming a substantial holder |
25/11/14 | | 8.26MB | Share |
|
CIR Change of Director's Interest Notice |
20/11/14 | | 74.25KB | Share |
|
CIR Change of Director's Interest Notice |
20/11/14 | | 71.54KB | Share |
|
CIR Change of Director's Interest Notice |
19/11/14 | | 74.12KB | Share |
|
CIR Change of Director's Interest Notice |
19/11/14 | | 74.36KB | Share |
|
PER News Report Misinterprets Substantial Notice |
18/11/14 | | 33.9KB | Share |
|
CIR Results of Annual General Meeting |
18/11/14 | | 55.47KB | Share |
|
CIR CEO's address to Annual General Meeting |
18/11/14 | | 1.45MB | Share |
|
CIR Chairman's Address to Annual General Meeting |
18/11/14 | | 47.35KB | Share |
|
PER Change in substantial holding from CIR |
17/11/14 | | 72.02KB | Share |
|
CIR Change in substantial holding |
14/11/14 | | 112.45KB | Share |
|
CIR Circadian Appendix 3B |
12/11/14 | | 177.62KB | Share |
|
CIR Completion of Rights Issue |
06/11/14 | | 42.62KB | Share |
|
CIR Becoming a substantial holder |
24/10/14 | | 70.73KB | Share |
|
CIR Placement Cleansing Notice |
22/10/14 | | 53.13KB | Share |
|
CIR Circadian Appendix 3B |
22/10/14 | | 158.83KB | Share |
|
CIR Circadian Annual General Meeting 2014 |
17/10/14 | | 643.55KB | Share |
|
CIR Circadian Letter to Shareholders |
10/10/14 | | 103.46KB | Share |
|
CIR Circadian Capital Raising Prospectus |
09/10/14 | PRICE SENSITIVE | 386.11KB | Share |
|
CIR Circadian Investor Presentation |
06/10/14 | | 1.39MB | Share |
|
CIR CIR Appendix 3B |
06/10/14 | | 155.21KB | Share |
|
CIR Circadian to Raise A$17.4 Million |
06/10/14 | PRICE SENSITIVE | 210.63KB | Share |
|
CIR Request for Trading Halt |
01/10/14 | | 43.37KB | Share |
|
CIR Trading Halt |
01/10/14 | PRICE SENSITIVE | 113.55KB | Share |
|
CIR Annual Report 2014 |
30/09/14 | | 2.52MB | Share |
|
CIR Circadian Allowed Key Patent for VEGFR-3 Traps in US |
23/09/14 | PRICE SENSITIVE | 177.09KB | Share |
|
CIR Preliminary Final Report |
29/08/14 | PRICE SENSITIVE | 263.21KB | Share |
|
CIR Opthea Awarded Grant for OPT-302 Manufacture |
23/06/14 | PRICE SENSITIVE | 125.98KB | Share |
|
CIRCircadian's VGX-100 Well Tolerated in Phase 1 Clinical Trial |
02/06/14 | | 302.44KB | Share |
|
CIRCircadian Appoints CFO and Company Secretary |
19/05/14 | | 86.47KB | Share |
|
CIRVGX-100 Phase 1 Study Selected for Presentation at ASCO 2014 |
15/05/14 | | 154.75KB | Share |
|
CIROpthea Completes Pre-IND Meeting with FDA |
12/05/14 | PRICE SENSITIVE | 130.88KB | Share |
|
CIROPT-302 reduces established wet AMD lesions in the mouse |
06/05/14 | PRICE SENSITIVE | 678.8KB | Share |
|
CIRCEO Terms of Employment |
23/04/14 | PRICE SENSITIVE | 202.72KB | Share |
|
CIRHalf Year Report & Accounts |
21/02/14 | PRICE SENSITIVE | 1.06MB | Share |
|
CIRCircadian Appoints CEO and Managing Director |
21/02/14 | PRICE SENSITIVE | 260.43KB | Share |
|
CIROpthea Signs Cell Line Commercial License Agreement |
14/01/14 | PRICE SENSITIVE | 574.45KB | Share |
|
CIRAppendix 3Z - Final Directors Interest Notice |
10/12/13 | | 13.35KB | Share |
|
CIRAppendix 3X - Initial Directors Interest Notice |
06/12/13 | | 69.33KB | Share |
|
CIRCircadian CEO and Board Changes |
03/12/13 | PRICE SENSITIVE | 21.25KB | Share |
|
CIRResults of Annual General Meeting |
29/11/13 | | 24.43KB | Share |
|
CIRCEOs Address To Annual General Meeting |
29/11/13 | | 1.37MB | Share |
|
CIRChairmans Address To Annual General Meeting |
29/11/13 | | 33.79KB | Share |
|
CIRAppendix 3Z - Final Directors Interest Notice |
29/11/13 | | 11.63KB | Share |
|
CIRDirector Resignation |
29/11/13 | | 21.22KB | Share |
|
CIRPhase 1b oncology trial completed |
27/11/13 | PRICE SENSITIVE | 371.7KB | Share |
|
CIRR&D Tax Incentive - Circadian To Receive Over $2.5m |
15/11/13 | PRICE SENSITIVE | 51.05KB | Share |
|
CIROpthea Signs Manufacturing Agreement |
30/10/13 | PRICE SENSITIVE | 471.6KB | Share |
|
CIRAnnual Report / Notice of AGM & Proxy Form |
28/10/13 | | 6.53MB | Share |
|
CIRPhase 1a clinical oncology trial with VGX-100 update |
17/10/13 | PRICE SENSITIVE | 110.33KB | Share |
|
CIR Change in substantial holding from CIR |
08/10/13 | | 132.18KB | Share |
|
CIRRevised AGM Details |
01/10/13 | | 23.45KB | Share |
|
CIRAnalyst Investment Report on Circadian Website |
11/09/13 | | 49.76KB | Share |
|
CIRNew Compamy Secretary |
10/09/13 | | 44.43KB | Share |
|
CIROpen Briefing |
28/08/13 | PRICE SENSITIVE | 288.12KB | Share |
|
CIRPreliminary Final Report |
27/08/13 | PRICE SENSITIVE | 648.19KB | Share |
|
CIRCircadian moves to new South Yarra office |
15/07/13 | | 96.56KB | Share |